erymethionase / eryminase
|Product Candidate / PROGRAM||Drug substance||Indication||Discovery||Pre-clinical||Phase 1||Phase 2||Phase 3/ Pivotal||EMA/FDA review||Commercial Rights|
In addition to L-asparaginase, we plan to leverage the broad applicability of our ERYCAPS platform to develop additional novel product candidates.
Based on our preclinical research, we have identified two other amino acid metabolism targeting enzymes, methionine-γ-liase (MGL) and arginine deiminase (ADI), which we believe can benefit from being encapsulated in red blood cells. MGL and ADI degrade methionine and arginine respectively, two essential amino acids that are necessary for tumor cells to survive and proliferate.
We are pursuing preclinical development with erymethionase and eryminase, respectively MGL and ADI encapsulated in RBCs.